Integra Lifesciences' Q4 Earnings Come In Above Expectations, Issues Soft Q1 Guidance

  • Integra Lifesciences Holdings Corp (NASDAQ: IARTreported Q4 adjusted EPS $0.84 better than the consensus estimate of $0.73 and revenues of $388.6 million in line with expectations.
  • Revenues declined 1.6% Y/Y on a reported basis and a decrease of 1.5% on an organic basis, as the COVID-19 pandemic negatively impacted the surgical procedure volumes.
  • The largest year-over-year revenue decline rates occurred in April, and surgical procedure volumes recovered over the balance of 2020. In Q4, surgical procedure volumes increased 5% sequentially.
  • Adjusted net income of $71.3 million improved from $58.9 million in the prior-year quarter, primarily driven by the Company's actions to reduce operating expenses during the pandemic to mitigate the impact of lower sales.
  • Adjusted EBITDA was $102.7 million, higher than $91.6 million a year ago. Cash flows from operations reached $80.3 million.
  • The Company ended the quarter with $470.2 million in cash and cash equivalents, $1.2 billion in undrawn revolver capacity, and a consolidated total leverage ratio of 3.0x.
  • For Q1 2021, the Company expects revenues from $345 million to $355 million, marginally lower than the consensus of $359.9 million. It sees adjusted EPS of $0.54 to $0.58 below the consensus estimate of $0.64.
  • For 2021, Integra sees revenues in a range of $1.52 billion to $1.53 billion, short of $1.54 billion consensus and adjusted EPS of $2.86 to $2.93, compared to consensus of $2.92.
  • The Company expects a reported revenue contribution from ACell in the range of $83 million to $88 million for 2021, with approximately $14 million to $15 million in Q1 of 2021. Integra completed the acquisition of ACell last month.
  • Price Action: IART closed 2.4% higher at $71.15 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsHealth CareGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!